Ono Pharmaceutical is expanding its scope in oncology with a $2.4 billion deal to buy Deciphera Pharmaceutical, a company that has one commercialized cancer therapy and a drug pipeline that includes a ...
On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...
OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, ...
ONO, as a Global Specialty Pharma company, is committed to delivering innovative new drugs to patients around the world. As a part of our medium-term management plan, ONO aims to reinforce our ...
In a $2.4 billion deal, Deciphera Pharmaceuticals Inc. is merging with Ono Pharmaceutical Co. Ltd. Ono is acquiring all of Deciphera’s outstanding stock shares for $25.60 each in cash. The merger ...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today ...
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
It was a busy week in the biotech sector with earnings reports from bigwigs Gilead Sciences, Inc. and GSK plc. Mergers and acquisitions continue to be in the spotlight as pharma and biotech majors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results